Table 1 Characteristics of the Phase III Trial Children (5–17 months)

Ghana

(N = 992)

Malawi

(N = 771)

Gabon

(N = 664)

Sex

Female

483 (48.7%)

383 (49.7%)

307 (46.2%)

Male

509 (51.3%)

388 (50.3%)

357 (53.8%)

Age at Vaccination Series Completion (Days)

Median (IQR)

461 (333.5, 539)

411.5 (316, 502.75)

385 (270.5, 495.5)

Min - Max

216–724

211–700

197–636

Missing

9

9

13

Vaccine Status

RTS,S/AS01 (4 dose)

332 (33.5%)

253 (32.8%)

218 (32.8%)

RTS,S/AS01 (3 dose)

330 (33.3%)

263 (34.1%)

223 (33.6%)

Control

330 (33.3%)

255 (33.1%)

223 (33.6%)

Estimated Background Malaria Incidence (Cases per Person-Year)

Median (IQR)

2.30 (1.69, 2.81)

0.24 (0.18, 0.32)

0.30 (0.15, 0.50)

Min - Max

0.85–4.45

0.08–2.47

0.04–0.92

Missing

4

1

134

Parasitemia during the Vaccination Series

Yes

230 (23.2%)

37 (4.8%)

26 (3.9%)

No

762 (76.8%)

734 (95.2%)

638 (96.1%)